Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues

The decision to pursue a monoclonal antibody (mAb) as a therapeutic for disease intervention requires the assessment of many factors, such as target-biology, including the total target burden and its accessibility at the intended site of action, as well as mAb-specific properties like binding affini...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:MAbs
Autores principales: Conner, Kip P., Pastuskovas, Cinthia V., Soto, Marcus, Thomas, Veena A., Wagner, Mylo, Rock, Dan A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188401/
https://ncbi.nlm.nih.gov/pubmed/32310023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2020.1746520
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares